Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Theravance Biopharma ( (TBPH) ).
On December 8, 2025, Theravance Biopharma held a virtual key opinion leader event for investors, focusing on its investigational product Ampreloxetine, which is being studied for treating symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. The company also announced its 2026 Annual General Meeting of Shareholders scheduled for June 12, 2026, in Dublin, Ireland. The event highlighted the company’s strong financial position, with a cash balance of $332.7 million as of September 30, 2025, and its strategic focus on advancing in-house developed assets through approval and commercialization. The upcoming Phase 3 data for Ampreloxetine is expected to be a significant catalyst for the company, aiming to address an underserved patient population in the U.S.
The most recent analyst rating on (TBPH) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.
Spark’s Take on TBPH Stock
According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.
Theravance Biopharma’s overall stock score reflects a strong earnings call performance and positive technical indicators, suggesting bullish momentum. Financial performance shows improvement but is tempered by operational challenges. The valuation indicates high growth expectations, though the stock may be overvalued. The absence of corporate events outside the earnings call did not impact the score.
To see Spark’s full report on TBPH stock, click here.
More about Theravance Biopharma
Theravance Biopharma is a commercial-stage biotechnology company focused on developing and commercializing respiratory and neurological disease therapies. The company is known for its cash-generating product YUPELRI and is actively involved in advancing its investigational therapy, Ampreloxetine, for neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA).
Average Trading Volume: 426,501
Technical Sentiment Signal: Buy
Current Market Cap: $940M
See more data about TBPH stock on TipRanks’ Stock Analysis page.